The Data Access Committee that surveys the appeals for data derived from the study "An oncogenic enhancer-rearrangement causes concomitant deregulation of EVI1 and GATA2 in leukemia" originating from the department Hematology at the Erasmus Medical Center (acronym ERASMUSMC-HEMA).
|Dac ID||Contact Person||Access Information|
|EGAC00001000162||Remco M. Hoogenboezem||r [dot] hoogenboezem [at] erasmusmc [dot] nl||No additional information is available|
This DAC controls 2 datasets:
|EGAD00001000727||Targeted resequencing on the specific regions chr3:126036241-130672290 and chr3:157712147-175694147 in hg19 centered on the chromosomal regions 3q21 and 3q26 respectively. The focus lies on the detection of the exact breakpoints in Acute Myeloid Leukemia (AML) patients having acquired a inv(3)(q21q26) or t(3;3)(q21;q26). This dataset contains all information to detect all structural variants contained within these regions, including the 3q-aberrations inducing the overexpression of the proto-oncogene EVI1.||Illumina HiSeq 2500;||38|
|EGAD00001000726||In total 30 Acute Myeloid Leukemias with an acquired inv(3)(q21q26) or t(3;3)(q21;q26) have been characterized by whole transcriptome sequencing (RNA-Seq). The 3q-aberration leads to overexpression of the proto-oncogene EVI1, but the mechanism of overexpression has thus far been elusive. The RNA-Seq was integral in determining the precise enhancer inducing the overexpression and led to other key discoveries.||Illumina HiSeq 2500;||30|